Zynerba Pharmaceuticals (ZYNE) Trading 0.5% Higher

Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded up 0.5% on Thursday . The company traded as high as $10.24 and last traded at $9.71. 65,339 shares were traded during trading, a decline of 80% from the average session volume of 321,085 shares. The stock had previously closed at $9.66.

A number of equities research analysts recently weighed in on the company. ValuEngine downgraded Zynerba Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Thursday, March 15th. Seaport Global Securities reaffirmed a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, March 13th. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, March 13th. Finally, HC Wainwright set a $23.00 price objective on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $17.86.

The firm has a market capitalization of $131.00, a price-to-earnings ratio of -4.10 and a beta of 4.94.



Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). During the same period last year, the company posted ($0.71) earnings per share. sell-side analysts anticipate that Zynerba Pharmaceuticals will post -2.63 EPS for the current year.

In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp purchased 10,000 shares of the stock in a transaction on Thursday, March 22nd. The stock was acquired at an average price of $9.28 per share, with a total value of $92,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.91% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ZYNE. The Manufacturers Life Insurance Company acquired a new stake in Zynerba Pharmaceuticals in the second quarter worth about $158,000. Engineers Gate Manager LP acquired a new stake in Zynerba Pharmaceuticals in the third quarter worth about $263,000. Alliancebernstein L.P. acquired a new stake in Zynerba Pharmaceuticals in the fourth quarter worth about $264,000. Wells Fargo & Company MN boosted its holdings in Zynerba Pharmaceuticals by 3,759.5% in the third quarter. Wells Fargo & Company MN now owns 34,079 shares of the company’s stock worth $285,000 after acquiring an additional 33,196 shares in the last quarter. Finally, California State Teachers Retirement System acquired a new stake in Zynerba Pharmaceuticals in the second quarter worth about $343,000. 28.92% of the stock is owned by institutional investors and hedge funds.

WARNING: “Zynerba Pharmaceuticals (ZYNE) Trading 0.5% Higher” was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://dakotafinancialnews.com/2018/04/14/zynerba-pharmaceuticals-zyne-trading-0-5-higher.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply